Vectorite Biomedical Inc.

4170

TW0004170006

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
16.8 ^TWD	+2.13%		+10.53%	-21.31%

04-25	Vectorite Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Vectorite Biomedical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Vectorite Biomedical Inc. cancelled the transaction announced on December 11, 2014

March 24, 2016

Vectorite Biomedical Inc. (GTSM:4170) announced a private placement of 12,000,000 shares on December 11, 2014.

On March 25, 2016, Vectorite Biomedical Inc. cancelled the transaction.

Latest news about Vectorite Biomedical Inc.

Vectorite Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-25	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-11	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-11	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-27	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-11	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-28	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-13	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-27	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Half Year Ended June 30, 2019	19-08-12	CI
Vectorite Biomedical Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-16	CI
Vectorite Biomedical Inc. cancelled the transaction announced on December 11, 2014	16-03-24	CI
Vectorite Biomedical Inc. announced a financing transaction.	14-12-10	CI
Vectorite Biomedical Inc. announced that it has received TWD 150 million in funding.	14-06-27	CI
Vectorite Biomedical Inc. announced a financing transaction.	14-03-13	CI

Chart Vectorite Biomedical Inc.

Duration

Period

More charts

Vectorite Biomedical Inc is a Taiwan-based company mainly engaged in providing cell product commissioned production services and cell preparations. Products include dendritic cell (DC) vaccines, and natural killer (NK) cell preparations for cancer treatment. The Company also provides immune cell collection, processing and storage services, cell preparation safety testing services, anti-cancer immunity testing services, original design manufacturer (ODM)/ contract development and manufacturing organization (CDMO) services, related medical consulting services, and laboratory quality management services. Products are mainly sold domestically.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VECTORITE BIOMEDICAL INC.	-21.31%	22.64M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B